Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs Sanofi SA — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.89, while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA pays a 5.5% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Sanofi SA is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SHY | SNY | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $83.18 | $52.34 |
52-Week Low | $81.79 | $41.33 |
Market Cap | — | $104.83B |
Enterprise Value | — | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY, a US stock, trades at $81.955, down 0.04% on the day. Technical indicators show a bullish overall signal with bearish moving averages and neutral oscillators, while key support and resistance levels cluster around $82. Recent corporate actions include scheduled dividend payments of $0.24 per share through mid-2026, indicating stable income distribution.
The outlook for SHY is mixed, with technical momentum facing near-term resistance. Investment opportunities center on dividend consistency, but risks include market volatility and sensitivity to interest rate changes. Investors should weigh income stability against potential price stagnation amid evolving macroeconomic conditions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
